<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Proudfoot, Amanda E.I.</dc:creator>
  <dc:creator>Uguccioni, Mariagrazia</dc:creator>
  <dc:date>2016-05-19</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Chemokine biology is mediated by more complex interactions than simple monomolecular  ligand–receptor interactions, as chemokines can form higher order quaternary structures,  which can also be formed after binding to glycosaminoglycans (GAGs) on endothelial cells,  and their receptors are found as dimers and/or oligomers at the cell surface. Due to the  complexity of the chemokine binding and signaling system, several mechanisms have been  proposed to provide an explanation for the synergy observed between chemokines in  leukocyte migration. Pioneering studies on interactions between different chemokines have  revealed that they can act as antagonists, or synergize with other chemokines. The  synergism can occur at different levels, involving either two chemokine receptors triggered  simultaneously or sequentially exposed to their agonists, or the activation of one type of  chemokine receptor triggered by chemokine heterocomplexes. In addition to the several  chemokines that, by forming a heterocomplex with chemokine receptor agonists, act as  enhancers of molecules of the same family, we have recently identified HMGB1, an  endogenous damage-associated molecular patterns (DAMPs) molecule, as an enhancer of  the activity of CXCL12. It is now evident that synergism between chemokines is crucial at  the very early stage of inflammation. In addition, the low-affinity interaction with GAGs has  recently been shown to induce cooperativity allowing synergy or inhibition of activity by  displacement of other ligands.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/318873</dc:identifier>
  <dc:identifier>https://n2t.net/ark:/12658/srd1318873</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/318873/files/Proudfoot_FI_2016.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2016.00183</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1318873</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Frontiers in immunology. - 2016, vol. 7, p. 183</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Chemokines</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cell migration</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Synergy</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Oligomerization</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Glycosaminoglycan</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/57/59</dc:subject>
  <dc:title xmlns:ns6="xml" ns6:lang="en">Modulation of chemokine responses : synergy and cooperativity</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
